NASDAQ: ACBAurora Cannabis Inc Stock
$0.51-0.01 (-1.92%)
Updated Jun 5, 2023
ACB Price
$0.51
Fair Value Price
$1.31
Market Cap
$175.27M
52 Week Low
$0.49
52 Week High
$1.94
P/E
-0.09x
P/B
0.42x
P/S
1.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$159.09M
Earnings
-$1.28B
Gross Margin
-13.1%
Operating Margin
-806.45%
Profit Margin
-829%
Debt to Equity
0.77
Operating Cash Flow
-$115M
Beta
1.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ACB Overview
Aurora Cannabis Inc. produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients. It also sells vaporizers; consumable vaporizer accessories; and herb mills for using CanniMed herbal cannabis products, as well as grinders and vaporizer lockable containers. In addition, the company engages in the development of medical cannabis products at various stages of development, including oral, topical, edible, and inhalable products; and operation of CanvasRX, a network of cannabis counseling and outreach centers. Further, it provides patient counselling services; design and construction services; and cannabis analytical product testing services. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, Woodstock, and WMMC. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACB ($0.51) is undervalued by 60.67% relative to our estimate of its Fair Value price of $1.31 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACB ($0.51) is significantly undervalued by 60.67% relative to our estimate of its Fair Value price of $1.31 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
ACB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACB due diligence checks available for Premium users.
Be the first to know about important ACB news, forecast changes, insider trades & much more!
ACB News
Valuation
ACB fair value
Fair Value of ACB stock based on Discounted Cash Flow (DCF)
Price
$0.51
Fair Value
$1.31
Undervalued by
60.97%
ACB ($0.51) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACB ($0.51) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ACB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
14.98x
Market
53.21x
ACB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
1.78x
ACB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACB's financial health
Profit margin
Revenue
$45.0M
Net Income
-$51.7M
Profit Margin
-114.7%
ACB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ACB's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$747.3M
Liabilities
$313.0M
Debt to equity
0.77
ACB's short-term assets ($408.11M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACB's short-term assets ($408.11M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$44.3M
Investing
$10.6M
Financing
-$45.5M
ACB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ACB vs Pharmaceutical Stocks
Aurora Cannabis Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.